IgM-enriched Immunoglobulin Attenuates Systemic Endotoxin Activity in Early Severe Sepsis
NCT02444871 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 30
Last updated 2015-05-28
Summary
The purpose of this study is to evaluate the effect of IgM-enriched immunoglobulins (Pentaglobin) on the endotoxin activity, conventional coagulation parameters, viscoelastic and aggregometric measurements of patients with severe sepsis.
Conditions
Sponsors & Collaborators
-
Goethe University
lead OTHER
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2013-01-31
- Primary Completion
- 2013-07-31
- Completion
- 2013-07-31
Countries
- Germany
Study Locations
More Related Trials
-
The Role of Myristic Acid in Serum for Early Diagnosis of Sepsis and Comparison With Selected Biomarkers of Sepsis
NCT03314831 ·Status: COMPLETED
-
Interest of the Balance of Pro-coagulating and Profibrinolytis Activities of the Microparticles (MP) in the Prognosis of Septic Shock
NCT02062970 ·Status: UNKNOWN ·Phase: NA
-
The Effects of Immunostimulation With GM-CSF or IFN-y on Immunoparalysis Following Human Endotoxemia
NCT01374711 ·Status: COMPLETED ·Phase: NA
-
The Utility of Ischemia Modified Albumin (IMA) in Sepsis
NCT00448968 ·Status: COMPLETED
-
Dysfunctional Myelopoiesis and Myeloid-Derived Suppressor Cells in Sepsis
NCT05110937 ·Status: RECRUITING
-
The Early Coagulopathy for the Prognosis in Sepsis
NCT04582188 ·Status: UNKNOWN
-
Mediators of Inflammation, Prognostic Markers and Genetic Polymorphisms in Patients With Sepsis
NCT01535534 ·Status: UNKNOWN
-
The Role of Emergency Neutrophils and Glycans in Postoperative and Septic Patients
NCT04117568 ·Status: TERMINATED
-
Prospective, Randomized Trial of Personalized Medicine With Pentaglobin® After Surgical Infectious Source Control in Patients With Peritonitis
NCT03334006 ·Status: RECRUITING ·Phase: PHASE2
-
Early Tranexamic Acid and Modulating the Inflammatory Response in Sepsis
NCT04910464 ·Status: RECRUITING ·Phase: PHASE3
-
Establishment of Early Diagnosis and Monitoring Model for Sepsis Patients
NCT04974411 ·Status: UNKNOWN
-
The Predictive Value of Hepatocyte Growth Factor and Soluble Receptor s-Met in Sepsis
NCT03340649 ·Status: UNKNOWN
-
Acute Phase Proteins as Early Markers in Sepsis
NCT00641355 ·Status: UNKNOWN
-
Endotoxin Activity Assay and Microcirculation in Severe Sepsis
NCT02452138 ·Status: UNKNOWN
-
Reconstruction of Monocytic Immunocompetence by Granulocyte-macrophage-colony Stimulating Factor (GM-CSF) in Patients With Severe Sepsis and Septic Shock
NCT00252915 ·Status: COMPLETED ·Phase: PHASE2
-
Platelet Reactivity in Septic Shock
NCT03716310 ·Status: COMPLETED
-
Effect of EGDT on Hepatic Perfusion in Patients With Septic Shock
NCT02060773 ·Status: UNKNOWN
-
Mediators of Inflammation, Prognostic Markers and Genetic Polymorphisms in Patients With Sepsis
NCT00222222 ·Status: COMPLETED ·Phase: NA
-
A Blood Test to Diagnose Sepsis in Symptomatic Adults and Children
NCT05142813 ·Status: UNKNOWN
-
Inflammatory Mediators in Early Sepsis
NCT02692118 ·Status: UNKNOWN
-
Sepsis Post Market Observational Study and Potential Reduction of Time to Antibiotics - Baylor S&W
NCT04291417 ·Status: COMPLETED
-
Pro-inflammatory Role of Blood Platelets in Critically Ill Patients With Septic Shock.
NCT04080453 ·Status: COMPLETED
-
Biomarkers for the Early Identification of Sepsis in the Emergency Department
NCT02707718 ·Status: COMPLETED
-
Gelatin in ICU and Sepsis
NCT02715466 ·Status: TERMINATED ·Phase: PHASE4
-
Role of 'Pentoxifylline and or IgM Enriched Intravenous Immunoglobulin in the Treatment of Neonatal Sepsis'
NCT01006499 ·Status: UNKNOWN ·Phase: PHASE4